Chinese biopharmaceutical company Innovent Biologics has entered an agreement with Shenzhen Chipscreen Biosciences to study the use of its Tyvyt (sintilimab) and IBI305 in combination with Chidamide for the treatment of advanced colorectal cancer.

Tyvyt is a fully human anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody, while IBI305 is a recombinant humanised anti-vascular endothelial growth factor (anti-VEGF) monoclonal antibody. IBI305 is a biosimilar candidate to bevacizumab.

Chidamide is Chipscreen Biosciences’ selective inhibitor of class I (subtypes 1, 2, 3) and IIb (subtype 10) histone deacetylases (HDACs).

As per the terms of the agreement, the companies will jointly evaluate the potential applications of the combination therapy in China. The partners will focus on both the safety and tolerability of the combination treatment.

Innovent Biologics chief scientific officer Kerry Blanchard said: “Chidamide, a novel epigenetic modulating agent discovered in China, seems to reverse patient resistance to immune therapy in early clinical studies.

“We are pleased to be partnering with Chipscreen Biosciences to explore combination therapy with Sintilimab, IBI305, and Chidamide in colorectal cancer. We hope this collaboration will eventually benefit those patients in need.”

“We are pleased to be partnering with Chipscreen Biosciences to explore combination therapy with Sintilimab, IBI305, and Chidamide in colorectal cancer. We hope this collaboration will eventually benefit those patients in need.”

Chidamide received marketing clearance from the China Food and Drug Administration (CFDA) in December 2014. The drug’s initial indication is for the treatment of relapsed and refractory peripheral T-cell lymphoma.

It is also being investigated as a single agent or combination therapy for other blood cancers, solid tumours and HIV.

Chipscreen Biosciences executive vice-president Zhiqiang Ning said: “We look forward to partnering with Innovent to explore a potential clinical application with the combination regimen of immune check-point inhibitor, angiogenesis inhibitor and epigenetic modulator in this indication.”

Tyvyt has the National Medical Products Administration (NMPA) marketing approval for relapsed or refractory classical Hodgkin’s lymphoma (r/r cHL). It is also under evaluation for other cancers.

NMPA accepted new drug application (NDA) of IBI305 last month.